Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Net Income towards Common Stockholders (2022 - 2025)

Historic Net Income towards Common Stockholders for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to -$47.2 million.

  • Axsome Therapeutics' Net Income towards Common Stockholders rose 2689.24% to -$47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$229.5 million, marking a year-over-year increase of 2619.57%. This contributed to the annual value of -$287.2 million for FY2024, which is 2005.45% down from last year.
  • Per Axsome Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$47.2 million for Q3 2025, which was up 2689.24% from -$47.9 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Net Income towards Common Stockholders ranged from a high of -$11.2 million in Q1 2023 and a low of -$98.6 million during Q4 2023
  • Its 4-year average for Net Income towards Common Stockholders is -$57.9 million, with a median of -$61.2 million in 2022.
  • Per our database at Business Quant, Axsome Therapeutics' Net Income towards Common Stockholders soared by 7164.41% in 2023 and then crashed by 50826.66% in 2024.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Net Income towards Common Stockholders stood at -$61.2 million in 2022, then tumbled by 61.06% to -$98.6 million in 2023, then increased by 24.05% to -$74.9 million in 2024, then soared by 36.95% to -$47.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$47.2 million for Q3 2025, versus -$47.9 million for Q2 2025 and -$59.4 million for Q1 2025.